A phase I study of gefitinib and irinotecan (IRN) in pediatric patients with refractory solid tumors.

被引：0
|
作者：
Furman, WL [1 ]
Daw, NC [1 ]
Crews, KR [1 ]
Stewart, CF [1 ]
McCarville, B [1 ]
Santana, VM [1 ]
Hawkins, D [1 ]
Rodriguez-Galindo, C [1 ]
Navid, F [1 ]
Houghton, PJ [1 ]
机构：
[1] St Jude Childrens Res Hosp, Memphis, TN 38105 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8521
引用
收藏
页码：804S / 804S
页数：1
相关论文
共 50 条
  • [1] Effect of gefitinib on the systemic disposition of intravenous irinotecan (IRN) in pediatric patients with refractory solid tumors.
    Iacono, LC
    Furman, WL
    Crews, KR
    Panetta, JC
    Freeman, BB
    Daw, NC
    Stewart, CF
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 129S - 129S
  • [2] Phase I study of regorafenib in combination with vincristine and irinotecan in pediatric patients with recurrent or refractory solid tumors.
    Casanova, Michela
    Bautista, Francisco
    Hewson, Quentin Campbell
    Makin, Guy
    Marshall, Lynley V.
    Verschuur, Arnauld
    Canete, Adela
    Corradini, Nadege
    Ploeger, Bart
    Mueller, Udo
    Zebger-Gong, Hong
    Chung, John Woojune
    Geoerger, Birgit
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.
    Meany, Holly Jane
    Dome, Jeffrey
    Hinds, Pamela S.
    Bagatell, Rochelle
    Shusterman, Suzanne
    Widemann, Brigitte C.
    Stern, Emily
    London, Wendy B.
    Kim, AeRang
    Fox, Elizabeth
    Rodriguez-Galindo, Carlos
    Minturn, Jane E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] A phase I study of oxaliplatin (OXA) and irinotecan (IRN) in pediatric patients with refractory solid tumors: A Children's Oncology Group study
    McGregor, L. M.
    Spunt, S. L.
    Furman, W. L.
    Stewart, C. F.
    Krailo, M. D.
    Speights, R.
    Houghton, P. J.
    Ivy, S. P.
    Blaney, S. M.
    Adamson, P. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] A phase I study of cetuximab and irinotecan in pediatric patients (pts) with refractory solid tumors
    Trippett, T. M.
    Kuttesch, J.
    Herzog, C.
    Boklan, J.
    Bagatell, R.
    Hunger, S.
    Arceci, R.
    Lu, H.
    Langer, C.
    Gore, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors.
    Wood, Paul James
    Strong, Robyn
    McArthur, Grant A.
    Michael, Michael
    Algar, Elizabeth
    Muscat, Andrea
    Rigby, Lin
    Ashley, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Effect of gefitinib on the bioavailability of oral irinotecan in children with refractory solid tumors.
    Crews, KR
    Furman, WL
    Panetta, JC
    Freeman, BB
    Iacono, LC
    Houghton, PJ
    Stewart, CF
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 130S - 130S
  • [8] Phase I Study of Bevacizumab Plus Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors
    Okada, Keiko
    Yamasaki, Kai
    Tanaka, Chika
    Fujisaki, Hiroyuki
    Osugi, Yuko
    Hara, Junichi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (11) : 1073 - 1079
  • [9] A phase I study of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors.
    McGregor, L. M.
    Spunt, S. L.
    Ward, D.
    Wu, J.
    Billups, C.
    Ivy, S. P.
    Santana, V. M.
    Fouladi, M.
    Furman, W. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Phase I and translational study of capecitabine, cisplatin, and irinotecan in patients with solid tumors.
    Verschraegen, CF
    Lee, FC
    Rabinowitz, I
    Mangalik, A
    Jennings, C
    Maestas, A
    Shen, Z
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 155S - 155S
12345